Enveric Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Enveric Biosciences
ENVB Stock  USD 2.91  0.16  5.21%   
Enveric Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Enveric Biosciences' valuation are provided below:
Gross Profit
8.2 M
Market Capitalization
2.8 M
Enterprise Value Revenue
1.7579
Revenue
35.4 M
Earnings Share
(119.64)
We have found one hundred twenty available fundamental signals for Enveric Biosciences, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to verify all of Enveric Biosciences prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road.

Enveric Biosciences Total Revenue

0.0

Check Enveric Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enveric Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 572.8 K, Interest Expense of 3.2 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 4.91, Dividend Yield of 31.8 K or PTB Ratio of 1.86. Enveric financial statements analysis is a perfect complement when working with Enveric Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Enveric Stock
Check out the analysis of Enveric Biosciences Correlation against competitors.
For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.

Enveric Biosciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3.4 M3.5 M13.4 M
Very volatile
Other Current Liabilities772.3 K812.9 K2.8 M
Very volatile
Total Current Liabilities1.6 M1.7 M5.6 M
Very volatile
Property Plant And Equipment Net232.8 K351.6 K211.5 K
Slightly volatile
Accounts Payable1.1 M600 K2.2 M
Slightly volatile
Cash2.3 M2.6 M3.4 M
Slightly volatile
Non Current Assets Total380.1 K400.2 K8.9 M
Pretty Stable
Cash And Short Term Investments2.4 M2.6 M3.4 M
Slightly volatile
Net Receivables245.4 K258.3 K3.7 M
Slightly volatile
Common Stock Shares Outstanding50.6 K48.2 K9.8 K
Slightly volatile
Liabilities And Stockholders Equity3.4 M3.5 M13.4 M
Very volatile
Other Current Assets322.4 K567.6 K477.1 K
Slightly volatile
Other Stockholder Equity130.7 M124.5 M58.8 M
Slightly volatile
Total Liabilities1.6 M1.7 M7.3 M
Very volatile
Total Current Assets4.2 M3.1 M6.1 M
Slightly volatile
Intangible Assets46.1 K48.5 K3.1 M
Slightly volatile
Short and Long Term Debt Total69.7 K73.4 K2.4 M
Pretty Stable
Short Term Debt69.7 K73.4 K1.5 M
Very volatile
Common Stock5.8 K6.1 K104.2 K
Slightly volatile
Common Stock Total Equity21.6 K22.7 K120.6 K
Slightly volatile
Property Plant And Equipment Gross960.2 K914.5 K341.7 K
Slightly volatile
Short Term Investments70.9 K74.6 K135.7 K
Slightly volatile
Long Term Debt1.9 M2.1 M2.3 M
Slightly volatile
Net Invested Capital1.4 M1.4 M17.1 M
Slightly volatile
Short and Long Term Debt5.5 M5.6 M4.9 M
Slightly volatile
Capital Stock5.8 K6.1 K259 K
Slightly volatile
Other Liabilities1.8 M2 M2.2 M
Slightly volatile
Property Plant Equipment376.6 K423.7 K462.4 K
Slightly volatile
Other Assets0.80.90.9824
Slightly volatile

Enveric Biosciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses12.2 M11.1 M18.4 M
Pretty Stable
Cost Of Revenue368.7 K388.1 K9.8 M
Pretty Stable
Total Operating Expenses7 M10.7 M9.5 M
Slightly volatile
Research Development2.3 M3.3 M1.9 M
Slightly volatile
Selling General Administrative6.5 M7.4 M6.7 M
Slightly volatile
Selling And Marketing Expenses70 K73.7 K1.9 M
Very volatile
Reconciled Depreciation288.6 K303.7 K2 M
Slightly volatile
Interest Income1871973.1 K
Slightly volatile

Enveric Biosciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow2.3 M2.6 M3.3 M
Slightly volatile
End Period Cash Flow2.3 M2.6 M3.4 M
Slightly volatile
Stock Based Compensation3.5 M1.8 M2.2 M
Slightly volatile
Dividends Paid2.5 T2.4 T1.2 T
Slightly volatile
Change To Netincome43.1 M41 M13.9 M
Slightly volatile
Change To Liabilities395.6 K440.7 K253.9 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.915.1625 K
Slightly volatile
Dividend Yield31.8 K30.3 K17.5 K
Slightly volatile
Days Sales Outstanding10767.1486.9616
Slightly volatile
Average Payables653.5 K614.1 K1.4 M
Pretty Stable
Stock Based Compensation To Revenue0.04480.02620.0302
Pretty Stable
Capex To Depreciation0.01090.01143.6485
Slightly volatile
EV To Sales5.035.2925 K
Slightly volatile
Payables Turnover0.550.583.0516
Slightly volatile
Sales General And Administrative To Revenue0.06290.06620.1909
Slightly volatile
Average Inventory7.1 K7.5 K23.8 K
Slightly volatile
Research And Ddevelopement To Revenue0.560.540.5284
Slightly volatile
Capex To Revenue1.0E-41.0E-40.0665
Slightly volatile
Cash Per Share58.4261.53.2 K
Slightly volatile
Days Payables Outstanding1.1 K649455
Slightly volatile
Income Quality0.690.738.6223
Pretty Stable
Intangibles To Total Assets0.01170.01230.347
Slightly volatile
Current Ratio3.632.111.9424
Slightly volatile
Receivables Turnover3.825.634.7806
Slightly volatile
Capex Per Share0.02690.02832.6 K
Slightly volatile
Average Receivables96 K101.1 K4.1 M
Slightly volatile
Revenue Per Share29.7 K16.3 K85.5 K
Slightly volatile
Interest Debt Per Share0.01920.02028.3 K
Slightly volatile
Debt To Assets0.00360.00380.2885
Slightly volatile
Graham Number22.4 K43.5 K45 K
Very volatile
Operating Cycle63.7867.1484.4022
Slightly volatile
Days Of Payables Outstanding1.1 K649455
Slightly volatile
Long Term Debt To Capitalization0.120.130.3566
Slightly volatile
Quick Ratio3.62.111.9289
Slightly volatile
Cash Ratio2.191.731.485
Slightly volatile
Days Of Sales Outstanding10767.1486.9616
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.860.91.2171
Slightly volatile
Fixed Asset Turnover454432380
Slightly volatile
Debt Ratio0.00360.00380.2885
Slightly volatile
Price Sales Ratio4.915.1625 K
Slightly volatile
Asset Turnover0.741.441.2303
Slightly volatile
Gross Profit Margin0.220.230.2932
Slightly volatile

Enveric Biosciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3 M3.1 M61 M
Slightly volatile
Enterprise Value507.5 K534.2 K46.9 M
Slightly volatile

Enveric Fundamental Market Drivers

Forward Price Earnings23.0947
Cash And Short Term Investments2.2 M

Enveric Upcoming Events

1st of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
1st of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Enveric Biosciences Financial Statements

Enveric Biosciences stakeholders use historical fundamental indicators, such as Enveric Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Enveric Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Enveric Biosciences' assets and liabilities are reflected in the revenues and expenses on Enveric Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Enveric Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-2.3 M-2.2 M
Cost Of Revenue388.1 K368.7 K
Stock Based Compensation To Revenue 0.03  0.04 
Sales General And Administrative To Revenue 0.07  0.06 
Research And Ddevelopement To Revenue 0.54  0.56 
Revenue Per Share16.3 K29.7 K
Ebit Per Revenue(0.14)(0.15)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CCitigroup
SSentinelOne
When determining whether Enveric Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enveric Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enveric Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enveric Biosciences Stock:
How To Invest In Enveric
Details
Is Enveric Stock a good investment?
Details
What is Enveric Biosciences' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Enveric Biosciences Correlation against competitors.
For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enveric Biosciences. Projected growth potential of Enveric fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Enveric Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(119.64)
Revenue Per Share
37.678
Quarterly Revenue Growth
(0.07)
Return On Assets
(1.30)
Return On Equity
(2.62)
Understanding Enveric Biosciences requires distinguishing between market price and book value, where the latter reflects Enveric's accounting equity. The concept of intrinsic value—what Enveric Biosciences' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Enveric Biosciences' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Enveric Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Enveric Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Enveric Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY